Garrity James A, Coleman Austin W, Matteson Eric L, Eggenberger Eric R, Waitzman David M
Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Am J Ophthalmol. 2004 Dec;138(6):925-30. doi: 10.1016/j.ajo.2004.06.077.
To report results of treatment with a monoclonal antibody (infliximab) directed against tumor necrosis factor alpha in seven patients with chronic and difficult-to-control idiopathic orbital inflammation (orbital myositis).
Observational case series.
Retrospective data were collected from seven patients who had idiopathic orbital inflammation and who were evaluated at three medical centers. All patients were treated with infliximab after the failure of traditional therapy, which included corticosteroids, radiotherapy, or anti-inflammatory chemotherapeutic agents.
All seven patients had a favorable response to treatment with infliximab. One patient with Behcet disease required supplemental oral corticosteroids. Pain, swelling, and need for concomitant corticosteroids were the primary measures of treatment success. Symptoms of comorbid disease in four patients also improved (Crohn disease in two, Behcet disease in one, and psoriasis in one). There were no untoward effects of treatment after a mean follow-up of 15.7 months (range, 4 to 31 months).
Treatment with infliximab appears to offer another therapeutic option in cases of recalcitrant or recurrent idiopathic orbital inflammation in which conventional treatment fails.
报告使用抗肿瘤坏死因子α单克隆抗体（英夫利昔单抗）治疗7例慢性且难以控制的特发性眼眶炎症（眼眶肌炎）患者的结果。
观察性病例系列。
收集来自三个医疗中心评估的7例特发性眼眶炎症患者的回顾性数据。所有患者在包括皮质类固醇、放疗或抗炎化疗药物在内的传统治疗失败后接受英夫利昔单抗治疗。
所有7例患者对英夫利昔单抗治疗均有良好反应。1例白塞病患者需要补充口服皮质类固醇。疼痛、肿胀和是否需要联合使用皮质类固醇是治疗成功的主要衡量指标。4例患者的合并症症状也有所改善（2例克罗恩病、1例白塞病和1例银屑病）。平均随访15.7个月（范围4至31个月）后，治疗无不良影响。
对于传统治疗失败的顽固性或复发性特发性眼眶炎症病例，英夫利昔单抗治疗似乎提供了另一种治疗选择。
